A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

被引：0
|
作者：
Bewersdorf, Jan Philipp
Verstovsek, Srdan
Derkach, Andriy
Masarova, Lucia
Pemmaraju, Naveen
Stein, Eytan M.
Mauro, Michael J.
Rampal, Raajit
Bose, Prithviraj
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7086
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
    Mora, Barbara
    Giorgino, Toni
    Guglielmelli, Paola
    Rumi, Elisa
    Maffioli, Margherita
    Rambaldi, Alessandro
    Caramella, Marianna
    Komrokji, Rami
    Gotlib, Jason
    Kiladjian, Jean Jacques
    Cervantes, Francisco
    Devos, Timothy
    Palandri, Francesca
    De Stefano, Valerio
    Ruggeri, Marco
    Silver, Richard T.
    Benevolo, Giulia
    Albano, Francesco
    Cavalloni, Chiara
    Barraco, Daniela
    Pietra, Daniela
    Barbui, Tiziano
    Rotunno, Giada
    Vannucchi, Alessandro Maria
    Passamonti, Francesco
    LEUKEMIA RESEARCH, 2018, 69 : 100 - 102
  • [42] CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY
    Mora, B.
    Giorgino, T.
    Guglielmelli, P.
    Rumi, E.
    Maffioli, M.
    Caramazza, D.
    Rambaldi, A.
    Caramella, M.
    Komrokji, R.
    Gotlib, J.
    Kiladjian, J. J.
    Cervantes, F.
    Devos, T.
    Palandri, F.
    De Stefano, V.
    Ruggeri, M.
    Silver, R. T.
    Benevolo, G.
    Albano, F.
    Merli, M.
    Pietra, D.
    Casalone, R.
    Barbui, T.
    Rotunno, G.
    Cazzola, M.
    Vannucchi, A. M.
    Passamonti, F.
    HAEMATOLOGICA, 2017, 102 : 117 - 118
  • [43] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis
    Mesal, Ruben A.
    Tefferi, Ayalew
    EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (03) : 471 - 479
  • [44] Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post - Polycythemia, Vera Myelofibrosis (PPV - MF), and Post Essential Thrombocythemia Myelofibrosis (PET - MF)
    Vargas, Pablo
    Ovilla, Roberto
    Alvarado, Martha
    Lopez, Manuel
    Hurtado Monroy, Rafael
    Carlos Solis, Juan
    Limon, Alejandro
    Agreda, Gladys
    Silva, Salvador
    Julio Kassack, Juan
    Zavala, Saida
    Aguilar, Carlos
    Baez, Enrique
    Barrera, Esperanza
    Osuna, Antonio
    Morales, Javier
    Herrera, Aquileo
    BLOOD, 2012, 120 (21)
  • [45] TUMOR LYSIS SYNDROME IN POST-POLYCYTHEMIA VERA MYELOFIBROSIS AFTER RUXOLITINIB INITIATION
    Chopra, Nitin
    Wu, Lesley
    Leibrandt, Ryan
    Rizk, Dahlia
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 1) : S603 - S603
  • [46] Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
    Palandri, Francesca
    Palumbo, Giuseppe A.
    Iurlo, Alessandra
    Polverelli, Nicola
    Benevolo, Giulia
    Breccia, Massimo
    Abruzzese, Elisabetta
    Tiribelli, Mario
    Bonifacio, Massimiliano
    Tieghi, Alessia
    Isidori, Alessandro
    Martino, Bruno
    Sgherza, Nicola
    D'Adda, Mariella
    Bergamaschi, Micaela
    Crugnola, Monica
    Cavazzini, Francesco
    Bosi, Costanza
    Binotto, Gianni
    Auteri, Giuseppe
    Latagliata, Roberto
    Ibatici, Adalberto
    Scaffidi, Luigi
    Penna, Domenico
    Cattaneo, Daniele
    Soci, Francesco
    Trawinska, Malgorzata
    Russo, Domenico
    Cuneo, Antonio
    Semenzato, Giampietro
    Di Raimondo, Francesco
    Aversa, Franco
    Lemoli, Roberto M.
    Heidel, Florian
    Reggiani, Maria L. B.
    Bartoletti, Daniela
    Cavo, Michele
    Catani, Lucia
    Vianelli, Nicola
    SEMINARS IN HEMATOLOGY, 2018, 55 (04) : 248 - 255
  • [47] Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group
    Mora, Barbara
    Guglielmelli, Paola
    Rumi, Elisa
    Maffioli, Margherita
    Barraco, Daniela
    Rambaldi, Alessandro
    Caramella, Marianna
    Komrokji, Rami S.
    Kiladjian, Jean-Jacques
    Gotlib, Jason
    Iurlo, Alessandra
    Cervantes, Francisco
    Devos, Timothy
    Palandri, Francesca
    De Stefano, Valerio
    Ruggeri, Marco
    Silver, Richard T.
    Albano, Francesco
    Benevolo, Giulia
    Cavalloni, Chiara
    Uccella, Silvia
    Accetta, Raffaella
    Siracusa, Claudia
    Agnoli, Stefania
    Merli, Michele
    Barbui, Tiziano
    Bertu, Lorenza
    Cazzola, Mario
    Vannucchi, Alessandro M.
    Passamonti, Francesco
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (01) : E1 - E3
  • [48] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
    Xin Du
    Daobin Zhou
    Frontiers of Medicine, 2016, 10 : 437 - 443
  • [49] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
    Xin Du
    Daobin Zhou
    Frontiers of Medicine, 2016, 10 (04) : 437 - 443
  • [50] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
    Du, Xin
    Zhou, Daobin
    FRONTIERS OF MEDICINE, 2016, 10 (04) : 437 - 443
12345